Page last updated: 2024-10-23

berberine and Body Weight

berberine has been researched along with Body Weight in 62 studies

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
" All clinical trials exploring the effects of berberine supplementation on indices of obesity were included."9.05The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020)
" To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated."7.96Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020)
" Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities."7.77Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011)
"A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0."6.80Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015)
"Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood."5.91Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023)
"Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents."5.46Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017)
"Osteoporosis was induced by bilateral ovariectomy."5.46Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017)
"Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity."5.43Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016)
"Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure."5.40Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014)
" All clinical trials exploring the effects of berberine supplementation on indices of obesity were included."5.05The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020)
" Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials."3.96Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020)
" To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated."3.96Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020)
"The present study aimed to investigate the effects of berberine (BRB) on spatial and learning memory, anxiety, acetylcholinesterase activity and cell death in an experimental model of intracerebroventricular streptozotocin (ICV-STZ) induced sporadic Alzheimer's-like dementia."3.83Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death. ( Abdalla, FH; Adefegha, SA; Baldissarelli, J; da Silva Bernardi, J; de Andrade, CM; de Oliveira, JS; Dornelles, GL; Lenz, LS; Magni, LP; Palma, TV; Pillat, MM; Rubin, MA; Signor, C, 2016)
" Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities."3.77Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011)
" donovani but was not as potent as meglumine antimonate (Glucantime), a standard drug for the treatment of leishmaniasis."3.68Berberine derivatives as antileishmanial drugs. ( Hanson, WL; Klayman, DL; Lovelace, JK; Vennerstrom, JL; Waits, VB, 1990)
"A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0."2.80Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015)
"00001) in a linear The dose-response relationship (Pearson r = - 0."2.61Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis. ( Long, Y; Ni, L; Tao, J; Wu, R; Xu, J; Yu, N; Yuan, X; Zhang, Y, 2019)
"Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood."1.91Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023)
" Alkaloids from Coptis chinensis are the main plasma components related to the toxic effects of TAZF."1.72Toxicity and toxicokinetics of the ethanol extract of Zuojin formula. ( Gao, Y; Li, L; Li, Y; Liu, X; Shan, D; Wang, Q; Wang, S; Yang, Z; Zhang, T; Zhang, Y, 2022)
"Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia."1.62Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021)
"Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese herbs and exhibits glucose lowering properties."1.62Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus. ( Chen, L; Cole, LK; Dolinsky, VW; Hatch, GM; Sparagna, GC; Vandel, M; Xiang, B; Zhang, M, 2021)
"Berberine has been reported to have pharmacological activity in adipose tissue to anti-obesity, while the mechanism remains unclear."1.62Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. ( Cao, L; He, Z; Jiang, X; Kong, J; Li, N; Ma, G; Song, X; Wang, Z; Wen, D; Xu, Y; Yang, F; Yu, T; Yu, Y; Zheng, L, 2021)
"Lung cancer is the worldwide leading cause of cancer-related death."1.518-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells. ( Han, B; Jiang, P; Li, X; Liu, L; Liu, W; Ma, W; Wu, S; Xu, H; Ye, X; Zhang, J, 2019)
" NAFLD model was established by high fat food, and rats were administrated with lovastatin, berberine, curcumin, berberine + curcumin at the dosage of 100, 100, 100, 50 + 50 mg/kg bw, respectively."1.48Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. ( Feng, WW; Kuang, SY; Liu, TS; Ma, ZJ; Pang, JY; Tu, C; Wang, JB; Wang, YH; Xiao, XH; Zang, QC; Zhao, YL, 2018)
"The rat model of hyperlipidemia was established by providing high-fat-diet (HFD) for 4 weeks."1.46Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats. ( Liu, L; Ni, H; Ren, F; Ren, J; Shen, T; Wei, H; Wei, J; Xu, S; Zhou, X, 2017)
"Osteoporosis was induced by bilateral ovariectomy."1.46Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017)
"Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents."1.46Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017)
" However, the implication of these mechanisms is unclear because of the low bioavailability of BBR."1.46Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. ( Aa, J; Aa, N; Cao, B; Chen, Q; Fei, F; Feng, D; Feng, S; Ge, C; Guo, GL; Guo, J; He, J; Huang, J; Kong, B; Pan, Y; Schumacher, JD; Shen, J; Sun, R; Wang, G; Wang, P; Yang, CS; Yang, N; Yu, X, 2017)
"Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular diseases."1.43Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. ( Ji, G; Li, M; Shu, X; Xu, H; Yang, L; Zhang, C; Zhang, L, 2016)
"Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity."1.43Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016)
" However, pharmacokinetic studies showed that berberine was poorly absorbed into the body so the levels of berberine in the blood and target tissues were far below the effective concentrations revealed."1.42A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. ( Aa, J; Cao, B; Gu, S; Hylemon, PB; Li, Y; Liu, L; Paletta, JL; Radlon, JM; Ridlon, JM; Sun, R; Tang, Y; Wang, G; Wu, X; Wu, XL; Zha, W; Zhao, C; Zhou, H, 2015)
"Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut."1.40Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. ( Li, M; Li, W; Ping, F; Wang, Z; Xiao, X; Yu, M; Zhang, H; Zhang, Q; Zheng, J, 2014)
"Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure."1.40Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014)
"CCl4-induced chronic liver fibrosis model in mice was established and activated rat hepatic stellate cell was treated with BBR."1.40Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase. ( Chen, L; Guan, F; Kan, M; Li, J; Pan, Y; Wang, Y; Xiao, X; Zhang, X, 2014)
" In the present study, we aimed to investigate the effect of berberine combined with atorvastatin on LOX‑1 and explore the underlying molecular mechanism involved."1.40Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. ( Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y, 2014)
" BBR solid lipid nanoparticles (SLNs) were prepared to achieve improved bioavailability and prolonged effect."1.39Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. ( Gao, DH; Li, XJ; Li, XM; Li, ZP; Liu, SH; Ou, ZM; Xue, M; Yang, MX; Yang, SY; Zhang, W, 2013)
"Doxorubicin, a very potent and often used anti-cancer drug, is largely limited due to the dose-related toxic effects."1.38Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. ( Chen, Y; Luo, Y; Tong, N; Zhang, J; Zhao, X, 2012)
"Treated with berberine for 4 weeks, elevated blood pressure and heightened levels of urine protein, blood urea nitrogen and serum creatinine in model rats were depressed significantly (P < 0."1.37[Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fat-salt-fructose diet]. ( Cai, Y; Li, HB; Lv, JH; Qi, CL, 2011)
"Berberine treatment significantly delayed the point of death after 20 Gy, but not 16 Gy, abdominal RT (p < ."1.36Effects of berberine against radiation-induced intestinal injury in mice. ( Chen, ZT; Hao, P; Hu, YD; Li, DZ; Li, GH; Tang, JL; Wang, DL; Wei, H; Zhang, YP, 2010)
"Wistar rat colon cancer model was induced by 1-2 dimethylhydrazine (DMH) (40 mg x kg(-1), sc) + 1% dextran sodium sulfate solution (DSS) (freely drinking)."1.36[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression]. ( Wu, K; Yang, J; Zhou, Q, 2010)
" However, the facts that berberine had low bioavailability and poor absorption through the gut wall indicated that berberine might exert its antihyperglycaemic effect in the intestinal tract before absorption."1.35Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. ( Deng, Y; Liu, L; Liu, X; Lu, S; Xie, L; Yu, S, 2008)
" In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase."1.35Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. ( Chen, L; Li, J; Liu, Y; Lv, X; Song, Y; Wang, C; Zhang, M, 2009)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (4.84)18.2507
2000's5 (8.06)29.6817
2010's44 (70.97)24.3611
2020's10 (16.13)2.80

Authors

AuthorsStudies
Zhang, M3
Yang, H1
Yang, E1
Li, J6
Dong, L1
Wang, S1
Zhang, T1
Liu, X6
Yang, Z1
Li, L2
Shan, D1
Gao, Y1
Li, Y3
Zhang, Y5
Wang, Q2
Li, C1
Leng, Q1
Hu, F1
Xu, Y4
Gong, S1
Yang, Y3
Zhang, H2
Li, X4
Zhang, W4
Xu, JH1
Yu, T2
Chen, QK1
Singh, R1
Bansal, Y1
Sodhi, RK1
Singh, DP1
Bishnoi, M1
Kondepudi, KK1
Medhi, B1
Kuhad, A1
Xiong, P1
Niu, L1
Talaei, S1
Kord-Varkaneh, H1
Clark, CCT1
Găman, MA1
Rahmani, J1
Dorosti, M1
Mousavi, SM1
Zarezadeh, M1
Taghizade-Bilondi, H1
Zhang, J3
Park, HJ1
Jung, E1
Shim, I1
Cole, LK1
Chen, L3
Sparagna, GC1
Vandel, M1
Xiang, B1
Dolinsky, VW1
Hatch, GM1
Di, S1
Han, L1
An, X1
Kong, R1
Gao, Z1
Wang, X2
Zhang, P1
Ding, Q1
Wu, H2
Wang, H1
Zhao, L1
Tong, X1
Ibrahim Fouad, G1
Ahmed, KA1
Ma, G1
Zheng, L1
Jiang, X1
Yang, F2
Wang, Z2
Li, N1
He, Z1
Song, X1
Wen, D1
Kong, J1
Yu, Y2
Cao, L1
Zhu, X1
Sun, Y1
Zhang, C2
Liu, H1
He, XF1
Zhang, L6
Zhang, CH1
Zhao, CR1
Li, H2
Zhang, LF1
Tian, GF1
Guo, MF1
Dai, Z1
Sui, FG1
Xiao, Y1
Tian, C1
Huang, T1
Han, B2
Wang, M1
Ma, H2
Li, Z1
Ye, X3
Zhou, X1
Ren, F1
Wei, H2
Liu, L5
Shen, T1
Xu, S1
Wei, J1
Ren, J1
Ni, H1
Feng, WW1
Kuang, SY1
Tu, C1
Ma, ZJ1
Pang, JY1
Wang, YH1
Zang, QC1
Liu, TS1
Zhao, YL1
Xiao, XH1
Wang, JB1
Xie, H1
Zhang, X5
Wang, T1
Hu, W1
Manicum, T1
Chen, H1
Sun, L1
Jiang, P1
Xu, H2
Liu, W1
Wu, S1
Ma, W1
Wu, L1
Xia, M1
Duan, Y1
Jiang, H1
Hu, X2
Yan, H1
Gu, Y1
Shi, H1
Gao, X2
Xu, J1
Long, Y1
Ni, L1
Yuan, X1
Yu, N1
Wu, R1
Tao, J1
Cicero, AF1
Tartagni, E1
Ertek, S1
Moghaddam, HK1
Baluchnejadmojarad, T1
Roghani, M1
Goshadrou, F1
Ronaghi, A1
Xue, M2
Yang, MX2
Li, XM2
Gao, DH1
Ou, ZM2
Li, ZP2
Liu, SH2
Li, XJ2
Yang, SY2
Pan, Y2
Kan, M1
Xiao, X2
Wang, Y2
Guan, F1
Li, MH1
Zhang, YJ1
Yu, YH1
Yang, SH1
Iqbal, J1
Mi, QY1
Li, B1
Wang, ZM1
Mao, WX1
Xie, HG1
Chen, SL1
Chi, L1
Peng, L1
Pan, N1
Zhang, Q1
Li, M2
Li, W1
Yu, M1
Ping, F1
Zheng, J1
Gu, S1
Cao, B2
Sun, R2
Tang, Y1
Paletta, JL1
Wu, X1
Wu, XL1
Zha, W1
Zhao, C1
Ridlon, JM1
Radlon, JM1
Hylemon, PB1
Zhou, H1
Aa, J2
Wang, G3
Zou, ZY1
Hu, YR1
Wang, YZ1
He, K2
Xia, S1
Xue, DF1
Li, XG1
Ye, XL1
Yan, HM1
Xia, MF1
Chang, XX1
Yao, XZ1
Rao, SX1
Zeng, MS1
Tu, YF1
Feng, R1
Jia, WP1
Liu, J1
Deng, W1
Jiang, JD1
Zhou, J3
Du, X1
Long, M1
Zhang, Z1
Zhou, S2
Qian, G1
Cao, Y1
Pan, Q1
Cai, W1
Shen, F1
Chen, GY1
Xu, LM1
Fan, JG1
Ye, L1
Yuan, H1
Shu, X1
Yang, L1
Ji, G1
Yang, W1
She, L1
Yu, K1
Yan, S1
Tian, X1
Ma, S1
He, Q1
Mei, D1
Sha, S1
Fan, S1
Wang, L2
Dong, M1
de Oliveira, JS1
Abdalla, FH1
Dornelles, GL1
Adefegha, SA1
Palma, TV1
Signor, C1
da Silva Bernardi, J1
Baldissarelli, J1
Lenz, LS1
Magni, LP1
Rubin, MA1
Pillat, MM1
de Andrade, CM1
Yang, N1
Kong, B1
Feng, D1
Yu, X1
Ge, C1
Huang, J1
Shen, J1
Wang, P1
Feng, S1
Fei, F1
Guo, J1
He, J1
Aa, N1
Chen, Q1
Schumacher, JD1
Yang, CS1
Guo, GL1
Qiu, YY1
Tang, LQ2
Wei, W2
Zhou, JY1
Zhou, SW1
Zhang, KB1
Tang, JL2
Guang, LX1
Ying, Y2
Li, DD1
Deng, Y1
Yu, S1
Lu, S1
Xie, L2
Xu, YC1
Guo, FJ1
Meng, Y1
Li, ML1
Tang, J1
Zhang, K1
Guang, L1
Huang, Y1
Li, D1
Wang, C1
Lv, X1
Song, Y1
Liu, Y1
Shen, YB1
Piao, XS1
Kim, SW1
Liu, P1
Li, GH1
Zhang, YP1
Chen, ZT1
Hu, YD1
Li, DZ1
Hao, P1
Wang, DL1
Wu, K1
Yang, J1
Zhou, Q1
Bhutada, P1
Mundhada, Y1
Bansod, K1
Tawari, S1
Patil, S1
Dixit, P1
Umathe, S1
Mundhada, D1
Dunnick, JK1
Singh, B1
Nyska, A1
Peckham, J1
Kissling, GE1
Sanders, JM1
Li, HB1
Cai, Y1
Qi, CL2
Lv, JH1
Xie, W1
Gu, D1
Cui, K1
Tang, YH1
Sun, ZL1
Fan, MS1
Li, ZX1
Huang, CG1
Chueh, WH1
Lin, JY1
Wu, D1
Wen, W1
Zhao, RX1
Lü, JH1
Zhong, CY1
Chen, YY1
Zhao, X1
Tong, N1
Chen, Y1
Luo, Y1
Yi, J1
Wang, D1
Wang, FL1
Zhu, LN1
Cai, M1
Haller, J1
Kiem, DT1
Makara, GB1
Miyahara, T1
Tezuka, Y1
Namba, T1
Suzuki, T1
Dowaki, R1
Watanabe, M1
Nemoto, N1
Tonami, S1
Seto, H1
Kadota, S1
Vennerstrom, JL1
Lovelace, JK1
Waits, VB1
Hanson, WL1
Klayman, DL1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282]Phase 2184 participants (Actual)Interventional2008-03-31Completed
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]Phase 4120 participants (Anticipated)Interventional2017-08-16Recruiting
Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals With Obesity and Non-alcoholic Fatty Liver Disease[NCT05647915]Phase 4326 participants (Anticipated)Interventional2022-12-15Not yet recruiting
The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365]Phase 1/Phase 224 participants (Actual)Interventional2019-06-21Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for berberine and Body Weight

ArticleYear
The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.
    Complementary therapies in clinical practice, 2020, Volume: 39

    Topics: Berberine; Body Mass Index; Body Weight; Dietary Supplements; Humans; Hypoglycemic Agents; Obesity;

2020
Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis.
    BMC cancer, 2019, Jun-17, Volume: 19, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Berberine; Berberis; Body Weight; Cricetina

2019
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
    Current vascular pharmacology, 2014, Volume: 12, Issue:4

    Topics: Animals; Berberine; Body Weight; Cardiovascular Diseases; Cinnamomum zeylanicum; Dietary Supplements

2014

Trials

2 trials available for berberine and Body Weight

ArticleYear
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis

2015
The effects of berberine on the magnitude of the acute inflammatory response induced by Escherichia coli lipopolysaccharide in broiler chickens.
    Poultry science, 2010, Volume: 89, Issue:1

    Topics: Animals; Berberine; Blood Cell Count; Body Weight; Cell Line; Chickens; Digestion; Hybridomas; Infla

2010

Other Studies

57 other studies available for berberine and Body Weight

ArticleYear
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
    International journal of molecular sciences, 2021, Dec-28, Volume: 23, Issue:1

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli

2021
Toxicity and toxicokinetics of the ethanol extract of Zuojin formula.
    BMC complementary medicine and therapies, 2022, Aug-15, Volume: 22, Issue:1

    Topics: Alkaloids; Animals; Berberine; Body Weight; Coptis; Drugs, Chinese Herbal; Ethanol; Female; Male; Ra

2022
Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes.
    Endocrinology, 2023, 02-11, Volume: 164, Issue:4

    Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Berberine; Body Weight; Growth Differentiation Fa

2023
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 118

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus,

2019
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
    Life sciences, 2020, Apr-15, Volume: 247

    Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female

2020
Berberine for Appetite Suppressant and Prevention of Obesity.
    BioMed research international, 2020, Volume: 2020

    Topics: Animals; Appetite Depressants; Berberine; Blood Glucose; Body Weight; Feeding Behavior; Leptin; Lipi

2020
Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus.
    The Journal of nutrition, 2021, 04-08, Volume: 151, Issue:4

    Topics: Adiposity; Animals; Berberine; Body Weight; Diabetes, Gestational; Diet, High-Fat; Dietary Supplemen

2021
In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications.
    Journal of ethnopharmacology, 2021, Aug-10, Volume: 276

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Computational Biology; Computer Simulation; Diabetes

2021
The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats.
    Tissue & cell, 2021, Volume: 73

    Topics: Animals; Apoptosis; Berberine; Biomarkers; Body Weight; Doxorubicin; Fibrillar Collagens; Inflammati

2021
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.
    International journal of biological sciences, 2021, Volume: 17, Issue:12

    Topics: Adipose Tissue, Brown; AMP-Activated Protein Kinases; Animals; Berberine; Blotting, Western; Body We

2021
Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays.
    Molecular medicine reports, 2017, Volume: 15, Issue:5

    Topics: Animals; Behavior, Animal; Berberine; Bifidobacterium; Body Weight; Depression; Disease Models, Anim

2017
Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
    Bosnian journal of basic medical sciences, 2017, Nov-20, Volume: 17, Issue:4

    Topics: Animals; Antioxidants; Berberine; Body Weight; Bone Density; Female; Femur; NF-kappa B; Osteoporosis

2017
8-Cetylberberine inhibits growth of lung cancer in vitro and in vivo.
    Life sciences, 2018, Jan-01, Volume: 192

    Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Biomarkers, Tumor; Bod

2018
Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.
    Lipids in health and disease, 2017, Dec-11, Volume: 16, Issue:1

    Topics: Administration, Oral; Animals; Apolipoprotein B-48; Berberine; Body Weight; Cholesterol, LDL; Coptis

2017
Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 99

    Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Berberine; Biologi

2018
Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 108

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Berberine; Blood Glucose; Body Weight; Bone Density; Deoxyguan

2018
8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells.
    Chemico-biological interactions, 2019, Feb-01, Volume: 299

    Topics: A549 Cells; Animals; Apoptosis; Berberine; Body Weight; Caspase 3; Cell Line, Tumor; Cyclin D; Cycli

2019
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
    Cell death & disease, 2019, 06-13, Volume: 10, Issue:6

    Topics: Adipocytes; Adipose Tissue, Brown; Adult; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agent

2019
Berberine chloride improved synaptic plasticity in STZ induced diabetic rats.
    Metabolic brain disease, 2013, Volume: 28, Issue:3

    Topics: Animals; Berberine; Body Weight; Data Interpretation, Statistical; Dentate Gyrus; Diabetes Mellitus,

2013
Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.
    International journal of nanomedicine, 2013, Volume: 8

    Topics: Administration, Oral; Analysis of Variance; Animals; Berberine; Body Weight; Eating; Glucose; Hypogl

2013
Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase.
    Life sciences, 2014, Mar-07, Volume: 98, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blotting, Western; Body Weight; Cell Proliferatio

2014
Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.
    European journal of pharmacology, 2014, Apr-05, Volume: 728

    Topics: Animals; Arterial Pressure; Autophagy; Berberine; Blotting, Western; Body Weight; Cardiomegaly; Card

2014
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
    International journal of molecular medicine, 2014, Volume: 34, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cul

2014
Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine.
    BMC complementary and alternative medicine, 2014, Jun-09, Volume: 14

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experime

2014
A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
    Molecular bioSystems, 2015, Volume: 11, Issue:2

    Topics: Administration, Oral; Animals; Berberine; Body Weight; Cholestanetriol 26-Monooxygenase; Cholesterol

2015
Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters.
    Fitoterapia, 2015, Volume: 105

    Topics: Animals; Berberine; Body Weight; Cholesterol; Cholesterol, LDL; Coptis; Diet, High-Fat; Disease Mode

2015
Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Body Weight; Carnitine O-Palm

2015
Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats.
    European journal of pharmacology, 2016, Mar-05, Volume: 774

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetic Neuropathies; Diet, High-Fat; Dietary Carbo

2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:3

    Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal

2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:3

    Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal

2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:3

    Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal

2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:3

    Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal

2016
Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 79

    Topics: Animals; Autoantibodies; Autoimmune Diseases; Berberine; Body Weight; Cytokines; Disease Models, Ani

2016
Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds.
    Journal of translational medicine, 2016, 08-05, Volume: 14, Issue:1

    Topics: Animals; Berberine; Body Weight; Diet, High-Fat; Feces; Gastrointestinal Microbiome; Hyperlipidemias

2016
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model.
    Molecular medicine reports, 2016, Volume: 14, Issue:4

    Topics: Animals; Berberine; Body Weight; Coptis; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Insu

2016
ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.
    Journal of molecular endocrinology, 2016, Volume: 57, Issue:4

    Topics: Animals; Autophagy; Berberine; Body Weight; Cell Line; Diet, High-Fat; Disease Models, Animal; Extra

2016
Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death.
    Neurotoxicology, 2016, Volume: 57

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Anxiety; Berberine; B

2016
Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Molecular pharmacology, 2017, Volume: 91, Issue:2

    Topics: Animals; Bacteria; Berberine; Bile Acids and Salts; Body Weight; CD36 Antigens; Diet, High-Fat; Fece

2017
Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.
    Molecular and cellular endocrinology, 2017, 03-05, Volume: 443

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Proliferation; Diabetic Nephropathies; Down-Reg

2017
Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.
    Biological & pharmaceutical bulletin, 2008, Volume: 31, Issue:6

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Chemical and Drug Induced Liver Injury; Diabetes Mel

2008
Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats.
    Die Pharmazie, 2008, Volume: 63, Issue:5

    Topics: alpha-Glucosidases; Animals; Berberine; Bile Acids and Salts; Blood Glucose; Body Weight; Data Inter

2008
Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus.
    Chinese medical journal, 2008, Nov-05, Volume: 121, Issue:21

    Topics: Acrolein; Animals; Berberine; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Glucose Tra

2008
Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats.
    European journal of pharmacology, 2009, Mar-15, Volume: 606, Issue:1-3

    Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Dietary Carbohydrates; Dietary Fat

2009
Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin.
    European journal of pharmacology, 2009, Oct-12, Volume: 620, Issue:1-3

    Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary

2009
Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies.
    Biochemical pharmacology, 2010, Apr-01, Volume: 79, Issue:7

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Cells, Cultured; Eating; Glucagon-Like Peptide 1; Hu

2010
Effects of berberine against radiation-induced intestinal injury in mice.
    International journal of radiation oncology, biology, physics, 2010, Aug-01, Volume: 77, Issue:5

    Topics: Amine Oxidase (Copper-Containing); Animals; Apoptosis; Berberine; Body Weight; Eating; Fatty Acid-Bi

2010
[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2010, Volume: 35, Issue:20

    Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Berberine; Body Weight; Colonic Neoplasms; Cycl

2010
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
    Behavioural brain research, 2011, Jun-20, Volume: 220, Issue:1

    Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber

2011
Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle.
    Toxicologic pathology, 2011, Volume: 39, Issue:2

    Topics: Animals; Berberine; Body Weight; Carcinogens; Female; Flavonolignans; Hydrastis; Liver Neoplasms; Ma

2011
[Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fat-salt-fructose diet].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2011, Volume: 34, Issue:3

    Topics: Animals; Berberine; Blood Pressure; Body Weight; Creatinine; Diet; Diet, High-Fat; Disease Models, A

2011
Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Animals; Araceae; Bacteroidetes; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Feces; Gastr

2011
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.
    Planta medica, 2012, Volume: 78, Issue:1

    Topics: Acrolein; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Cholesterol, HDL; Ch

2012
Protective effect of berberine on serum glucose levels in non-obese diabetic mice.
    International immunopharmacology, 2012, Volume: 12, Issue:3

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Energy Intake; Female; Gl

2012
Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, Jun-15, Volume: 19, Issue:8-9

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Cholesterol; Creatinine; Diabetes Mellitus, Experime

2012
Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:5

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Body Weight; Chemical and Dru

2012
Safety evaluation of main alkaloids from Rhizoma Coptidis.
    Journal of ethnopharmacology, 2013, Jan-09, Volume: 145, Issue:1

    Topics: 3T3-L1 Cells; Alkaloids; Animals; Berberine; Berberine Alkaloids; Blood Proteins; Body Weight; Copti

2013
Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.
    Molecular biology reports, 2013, Volume: 40, Issue:3

    Topics: Animals; Berberine; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabeti

2013
Do alpha-2 adrenoceptors modify coping strategies in rats?
    Psychopharmacology, 1995, Volume: 122, Issue:4

    Topics: Adaptation, Psychological; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Ag

1995
The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine.
    Biological & pharmaceutical bulletin, 1999, Volume: 22, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Apoptosis; Berberine; Body Weight; Bone Density; Bone Resorption; Ca

1999
Berberine derivatives as antileishmanial drugs.
    Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:5

    Topics: Animals; Antiprotozoal Agents; Berberine; Berberine Alkaloids; Body Weight; Cricetinae; Leishmaniasi

1990